Do you want to read an article? Please log in or register.
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
Macular Diseases
RECOMMENDED
Related content
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.
Macular Diseases
Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry
Eye (Lond)
Bhandari S, Squirrell D, Nguyen V, Wang N, Wells JM, Tan T, Barnes R, Barry R, Barthelmes D, Gillies M
doi: 10.1038/s41433-021-01509-x
RECOMMENDED
Macular Diseases
Changes in real-world treatment patterns for diabetic macular oedema from 2009-2019 and five-year outcomes: Data from the Fight Retinal Blindness! Registry
★ 1
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
doi: 10.1111/ceo.13781.
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.
COMMENTED
Macular Diseases
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Bhandari S, Mehta H, Viola F, Arnold J, Fraser-Bell S, Barthelmes D, Creuzot-Garcher C, Gillies M
doi: 10.1111/aos.14672
RECOMMENDED
Macular Diseases
Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry
★ 1
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
doi: 10.1111/ceo.13707.
Retinal Diseases
Intraocular Pressure Changes and VEGF Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry
Ophthalmol Retina.
Gabrielle PH, Nguyen V, Wolff B, Essex R, Young S, Hunt A, Gemmy Cheung CM, Arnold JJ, Barthelmes D, Creuzot-Garcher C, Gillies M, Fight Retinal Blindness! Study Group.
doi: 10.1016/j.oret.2020.06.020.
Macular Diseases
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/
COMMENTED
Macular Diseases
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
JAMA Ophthalmol.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.
doi: 10.1001/